Saturday, 06 June 2020


Oramed submits pre-IND for exenatide to FDA

02 August 2013 | Regulatory | By BioSpectrum Bureau

Oramed submits pre-IND meeting request to FDA for its oral exenatide capsule ORMD-0901

Oramed submits pre-IND meeting request to FDA for its oral exenatide capsule ORMD-0901

Singapore: Oramed Pharmaceuticals, a developer of oral drug delivery systems, submitted a pre-Investigational New Drug (pre-IND) meeting request to the US FDA for a US-based trial on its orally ingestible exenatide capsule, ORMD-0901.

Mr Nadav Kidron, CEO, Oramed, commented that, "We are very pleased to have submitted this pre-IND meeting request letter as part of our efforts to advance ORMD-0901 into US clinical trials. We look forward to the FDA's response and preparing ourselves accordingly in our efforts leading up to full IND submission on our second product."


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account